Life Sciences

  • Microbiome / Nutrition / Foodtech / Lifestyle
  • Medtech / Connected health / Digital health
  • Biotech & pharmaceuticals
  • Industrial Biotech & Cleantech
  • Animal health / Animal Feed & Nutrition

Read more

Digital Technologies

  • Fintech
  • Retailtech
  • Other digital innovative solutions
  • Hardware & telecom

Read more

Sport & Performance Capital

  • Sport-Health
  • Equipment
  • Food-Nutrition
  • IOT-Digital
  • Sports practice

Read more

Blue Economy

  • Sustainable aquaculture
  • Nutrition Cosmetics Health
  • Industrial Products & Biomaterials
  • Biopolymers and biopackaging
  • Digitalization Blue 3.0
  • Recycling, Bioremediation
  • Climate & Carbon
  • Bioenergies, hydrogen

Read more

News

  • MaaT Pharma Announces Positive Second DSMB Review of Ongoing Phase 2b Clinical Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT
    21 January 2025

    MaaT Pharma Announces Positive Second DSMB Review of Ongoing Phase 2b Clinical Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT

    MaaT Pharma (EURONEXT: MAAT – the “Company”), a...

  • Extending Insights to the Small Intestine: Cmbio™ Teams Up with Nimble Science
    21 January 2025

    Extending Insights to the Small Intestine: Cmbio™ Teams Up with Nimble Science

    Cmbio™, a global leader in multi-omics science and...

  • Cmbio® Acquires Eagle Genomics’ Assets to Enhance Multi-Omics Software and AI/ML capabilities of its Digital Biology Platform.
    10 January 2025

    Cmbio® Acquires Eagle Genomics’ Assets to Enhance Multi-Omics Software and AI/ML capabilities of its Digital Biology Platform.

    Cmbio®, a global leader in multi-omics science and...

  • MaaT Pharma Announces Positive Topline Results from the Pivotal Phase 3 ARES Study Evaluating MaaT013 in acute Graft-versus-Host Disease
    8 January 2025

    MaaT Pharma Announces Positive Topline Results from the Pivotal Phase 3 ARES Study Evaluating MaaT013 in acute Graft-versus-Host Disease

    The study met its primary endpoint with a significant...

  • MaaT Pharma Presented Positive Updated Data on MaaT013 in the Early Access Program at ASH 2024 Annual Meeting
    10 December 2024

    MaaT Pharma Presented Positive Updated Data on MaaT013 in the Early Access Program at ASH 2024 Annual Meeting

    These findings underscore MaaT013’s potential as a...